Lantern Pharma
LTRN
34 hedge funds and large institutions have $9.75M invested in Lantern Pharma in 2024 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 6 closing their positions.
476% more call options, than puts
Call options by funds: $1.19M | Put options by funds: $207K
97% more capital invested
Capital invested by funds: $4.95M → $9.75M (+$4.81M)
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
13% more funds holding
Funds holding: 30 → 34 (+4)
0.31% less ownership
Funds ownership: 10.63% → 10.32% (-0.31%)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$138K |
| 2 |
Jane Street
New York
|
+$133K |
| 3 |
Renaissance Technologies
New York
|
+$117K |
| 4 |
TAM
Tocqueville Asset Management
New York
|
+$102K |
| 5 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$80K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Carlson Capital
Dallas,
Texas
|
-$257K |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$252K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$133K |
| 4 |
MWM
Meridian Wealth Management
Lexington,
Kentucky
|
-$84.1K |
| 5 |
CM
CM Management
Gulf Breeze,
Florida
|
-$80.2K |
LTRN Hedge Fund Activity: Q1 2024 in Review
34 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q1 2024, worth a combined $9.75M — up 97% from $4.95M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new LTRN positions and 6 closed out — a net gain of 4 holders — while 8 added to existing stakes and 11 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $138K. The largest seller was Carlson Capital, exiting entirely with an estimated $257K sold.
- 34 institutional investors held Lantern Pharma (LTRN) as of Q1 2024, up from 30 in Q4 2023.
- Funds reported $9.75M of Lantern Pharma stock for Q1 2024, up 97% quarter-over-quarter.
- 10 funds opened new Lantern Pharma positions in Q1 2024 and 6 closed out, a net change of +4 holders.
- The largest Lantern Pharma buyer in Q1 2024 was Susquehanna International Group, an estimated $138K added.
- The largest Lantern Pharma seller in Q1 2024 was Carlson Capital, an estimated $257K sold.
Based on aggregated 13F filings for Q1 2024.